Method for forming a nanomedicinal composition

Patent metadata

Field	Value
Publication number	US-12280158-B2
Application number	US-202318193689-A
Country	US
Kind code	B2
Filing date	Mar 31, 2023
Priority date	Jun 17, 2022
Publication date	Apr 22, 2025
Grant date	Apr 22, 2025

Abstract

A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

First claim

The invention claimed is:

1. A method of forming a nanomedicinal composition, the method comprising:
mixing a metal organic framework and a porous silicate and/or an aluminosilicate matrix to form a nanocarrier;
combining the nanocarrier and an antioxidant in an impregnation solution thereby forming the nanomedicinal composition; and
isolating the nanomedicinal composition;
wherein the metal organic framework is a zeolitic imidazolate framework; and
the antioxidant is disposed in the pores and/or on a surface of the nanocarrier.

2. The method of claim 1 , wherein the porous silicate and/or the aluminosilicate matrix is at least one selected from the group consisting of MCM-41 and KIT-6.

3. The method of claim 2 , wherein the nanocarrier has a surface area of 225 to 750 m 2 /g, a pore volume of 0.25 to 0.85 cm 3 /g, and a mean pore size of 2 to 10 nm.

4. The method of claim 2 , wherein the porous silicate and/or aluminosilicate matrix is MCM-41 and the nanocarrier has a surface area of 450 to 750 m 2 /g, a pore volume of 0.25 to 0.65 cm 3 /g, and a mean pore size of 2 to 4 nm.

5. The method of claim 2 , wherein the porous silicate and/or the aluminosilicate matrix is KIT-6 and the nanocarrier has a surface area of 225 to 450 m 2 /g, a pore volume of 0.45 to 0.85 cm 3 /g, and a mean pore size of 5 to 10 nm.

6. The method of claim 1 , wherein the porous silicate and/or the aluminosilicate matrix is present in an amount of 1 to 20 wt % based on a total weight of the nanocarrier.

7. The method of claim 1 , wherein the metal organic framework comprises an imidazole moiety of formula I:

and is substantially free of a benzimidazole moiety of formula II:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and Re are each independently selected from the group consisting of a hydrogen, an optionally substituted C 1 -C 3 alkyl group, and an optionally substituted C 3 -C 6 cycloalkyl group.

8. The method of claim 7 , wherein the zeolitic imidazolate framework is ZIF-8.

9. The method of claim 1 , wherein the antioxidant is at least one selected from the group consisting of quercetin, rutin, coenzyme Q10, gallic acid, resveratrol, and curcumin.

10. The method of claim 9 , wherein the antioxidant is curcumin.

11. The method of claim 9 , wherein the antioxidant is resveratrol.

12. The method of claim 1 , wherein the antioxidant is present in the nanomedicinal composition in an amount of 5 to 50 wt %, based on a total weight of nanomedicinal composition.

13. The method of claim 1 , wherein the nanomedicinal composition is capable of reducing the viability of Blastocystis organisms by at least 75% when the nanomedicinal composition is present for 24 hours in an amount of 100 to 1000 μg/mL.

14. The method of claim 1 , wherein the mixing comprising ultrasonication.

15. The method of claim 1 , wherein the impregnation solution comprises an alcohol having 1 to 5 carbon atoms and the antioxidant is present in an amount of 0.5 to 3 mg/mL of impregnation solution.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Jermy B Rabindran
• Ravinayagam Vijaya
• Elbadry Ayman A

Classifications

• A61K31/12 Primary

  Ketones · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61K9/5115 Primary

  Inorganic compounds · CPC title

• A61K31/05

  Phenols {(cannabinoids A61K31/658)} · CPC title